Leerink Partnrs Has Negative Outlook of Revvity Q4 Earnings

Revvity, Inc. (NYSE:RVTY - Free Report) - Research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for shares of Revvity in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings per share of $1.37 for the quarter, down from their prior estimate of $1.38. The consensus estimate for Revvity's current full-year earnings is $4.84 per share. Leerink Partnrs also issued estimates for Revvity's FY2025 earnings at $5.08 EPS and FY2026 earnings at $5.72 EPS.

Other analysts have also issued research reports about the stock. TD Cowen lifted their price target on shares of Revvity from $141.00 to $144.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Raymond James dropped their price target on shares of Revvity from $146.00 to $140.00 and set an "outperform" rating for the company in a research note on Tuesday. Barclays reduced their price objective on Revvity from $140.00 to $135.00 and set an "overweight" rating on the stock in a research note on Monday, November 25th. Leerink Partners raised their target price on shares of Revvity from $130.00 to $135.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Finally, Sanford C. Bernstein downgraded Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price target for the company. in a report on Friday, January 10th. Five equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Revvity currently has an average rating of "Moderate Buy" and a consensus price target of $132.00.

Revvity Trading Down 1.0 %

NYSE RVTY traded down $1.19 on Wednesday, reaching $122.76. 936,430 shares of the company were exchanged, compared to its average volume of 799,648. The company has a current ratio of 3.56, a quick ratio of 2.97 and a debt-to-equity ratio of 0.40. The business's fifty day moving average price is $114.96 and its 200 day moving average price is $117.91. The stock has a market capitalization of $14.94 billion, a P/E ratio of 59.31, a price-to-earnings-growth ratio of 3.50 and a beta of 1.03. Revvity has a fifty-two week low of $97.32 and a fifty-two week high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.28 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.15. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The firm had revenue of $684.10 million for the quarter, compared to the consensus estimate of $679.66 million. During the same period last year, the firm posted $1.18 earnings per share. The company's revenue for the quarter was up 2.1% on a year-over-year basis.

Revvity declared that its board has approved a stock buyback program on Monday, November 4th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 6.5% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's board believes its stock is undervalued.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.23%. The ex-dividend date is Friday, January 17th. Revvity's dividend payout ratio (DPR) is 13.53%.

Insider Buying and Selling

In related news, insider Tajinder S. Vohra sold 5,492 shares of the business's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now directly owns 19,652 shares in the company, valued at $2,295,550.12. The trade was a 21.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.60% of the company's stock.

Hedge Funds Weigh In On Revvity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gladius Capital Management LP acquired a new stake in Revvity during the third quarter worth approximately $32,000. Continuum Advisory LLC raised its stake in shares of Revvity by 2,972.7% in the 3rd quarter. Continuum Advisory LLC now owns 338 shares of the company's stock valued at $43,000 after acquiring an additional 327 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in Revvity by 55.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock valued at $43,000 after purchasing an additional 138 shares during the period. EverSource Wealth Advisors LLC lifted its position in Revvity by 74.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company's stock worth $41,000 after acquiring an additional 167 shares in the last quarter. Finally, Avior Wealth Management LLC boosted its stake in shares of Revvity by 7,980.0% in the third quarter. Avior Wealth Management LLC now owns 404 shares of the company's stock valued at $52,000 after purchasing an additional 399 shares during the period. Institutional investors and hedge funds own 86.65% of the company's stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.